(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its use in the treatment of cancer.
This patent provides protection until 2037. ‘CLEC-1 is a CLR-type receptor that blocks the suppressive functions of myeloid cells and allows the reactivation of the T lymphocyte antitumor response’, specifies the biotechnology company.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
